Clinical Trials · NCT03444025
Neoadjuvant Goserelin for Triple Negative Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Kasr El Aini Hospital
- Enrollment
- 180
- Start date
- Mar 2018
- Locations
- See registry
- Primary endpoint
- pathologic complete response rate